Get the Stockscreener App
38.63
0.21%
-0.08
Exelixis Inc stock is traded at $38.63, with a volume of 1.51M.
It is down -0.21% in the last 24 hours and down -13.13% over the past month.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
See More
Previous Close:
$38.71
Open:
$38.74
24h Volume:
1.51M
Relative Volume:
0.45
Market Cap:
$10.40B
Revenue:
$2.17B
Net Income/Loss:
$521.27M
P/E Ratio:
21.82
EPS:
1.77
Net Cash Flow:
$633.79M
1W Performance:
+0.84%
1M Performance:
-13.13%
6M Performance:
+4.83%
1Y Performance:
+49.84%
1-Day Range:
$38.31
$38.85
1-Week Range:
$37.40
$38.85
52-Week Range:
$25.12
$49.62
Exelixis Inc Stock (EXEL) Company Profile
Name
Exelixis Inc
Sector
Industry
Phone
(650) 837-7000
Address
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Compare EXEL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
38.63 | 10.17B | 2.17B | 521.27M | 633.79M | 1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-08-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jun-24-25 | Upgrade | Stephens | Equal-Weight → Overweight |
| Feb-24-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-27-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-24-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-17-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-16-24 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-19-24 | Initiated | UBS | Neutral |
| Apr-11-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-19-23 | Initiated | BTIG Research | Buy |
| Dec-15-23 | Initiated | Citigroup | Buy |
| Sep-26-23 | Initiated | H.C. Wainwright | Buy |
| Aug-22-23 | Reiterated | Oppenheimer | Outperform |
| Aug-08-23 | Initiated | SVB Securities | Market Perform |
| Jul-11-23 | Resumed | Morgan Stanley | Equal-Weight |
| May-10-23 | Resumed | Piper Sandler | Overweight |
| Mar-09-23 | Initiated | Wells Fargo | Overweight |
| Jan-26-23 | Initiated | Credit Suisse | Outperform |
| Oct-18-22 | Initiated | JMP Securities | Mkt Outperform |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Nov-03-21 | Resumed | Jefferies | Buy |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-15-21 | Initiated | H.C. Wainwright | Buy |
| May-18-21 | Resumed | Goldman | Sell |
| Mar-31-21 | Initiated | Credit Suisse | Outperform |
| Mar-12-21 | Initiated | Wolfe Research | Outperform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| Mar-18-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Sep-17-18 | Initiated | Goldman | Neutral |
| Sep-10-18 | Initiated | Morgan Stanley | Underweight |
| May-11-18 | Reiterated | Needham | Buy |
| Oct-17-17 | Reiterated | Needham | Buy |
| Oct-17-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-16-17 | Reiterated | SunTrust | Buy |
| Sep-22-17 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-12-17 | Reiterated | Needham | Buy |
| Jul-14-17 | Initiated | SunTrust | Buy |
| Mar-31-17 | Initiated | Needham | Buy |
| Mar-16-17 | Initiated | Oppenheimer | Perform |
| Feb-28-17 | Downgrade | Stifel | Buy → Hold |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Oct-10-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-15-16 | Reiterated | Stifel | Buy |
View All
Exelixis Inc Stock (EXEL) Latest News
Exelixis (EXEL) Tumbles 16.8% as Q2 Earnings Disappoint - MSN
How to manage a losing position in Exelixis Inc.2025 Top Gainers & Stepwise Trade Signal Implementation - Newser
Developing predictive dashboards with Exelixis Inc. dataWeekly Volume Report & High Conviction Buy Zone Picks - Newser
Will Exelixis Inc. stock go up soonQuarterly Performance Summary & Daily Volume Surge Signals - Newser
Exelixis Inc. Flashes Rebound Signal in Oversold ConditionJuly 2025 Outlook & High Accuracy Investment Entry Signals - beatles.ru
Sector ETF performance correlation with Exelixis Inc.July 2025 Highlights & Daily Stock Trend Watchlist - Newser
When is the best time to exit Exelixis Inc.2025 Growth vs Value & Weekly Market Pulse Updates - Newser
Should you wait for a breakout in Exelixis Inc.Market Trend Report & Safe Capital Growth Tips - Newser
What candlestick patterns are forming on Exelixis Inc.Weekly Stock Analysis & Capital Efficiency Focused Ideas - Newser
Price momentum metrics for Exelixis Inc. explainedQuarterly Growth Report & Daily Entry Point Alerts - Newser
Will EXEL's Share Repurchase Program Boost Value for Investors? - sg.finance.yahoo.com
Can Exelixis Inc. Rally Enough to Break EvenJuly 2025 Opening Moves & Growth Focused Stock Reports - classian.co.kr
Is Exelixis Inc. stock forming a cup and handleBear Alert & Fast Gain Stock Trading Tips - thegnnews.com
Is Exelixis Inc. building a consolidation base2025 Big Picture & Real-Time Chart Breakout Alerts - Newser
BofA Hikes Exelixis, Inc. (EXEL) Target Amid CRC Caution - MSN
Live Scanner Shows Breakout on Exelixis Inc.Portfolio Return Summary & Weekly Breakout Opportunity Watchlist - newsimpact.co.kr
Exelixis reports Q2 rev. below consensus, net product revenues 2% lower YoY. - AInvest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc.EXEL - FinancialContent
H.C. Wainwright Maintains Buy on Exelixis (EXEL) Despite STELLAR-305 Phase 3 Setback - MSN
Signal strength of Exelixis Inc. stock in tech scannersInflation Watch & Community Shared Stock Ideas - Newser
H.C. Wainwright Maintains Buy Rating on Exelixis Despite STELLAR-305 Phase 3 Setback - AInvest
What makes Exelixis Inc. stock price move sharplyStop Loss & Free Community Supported Trade Ideas - thegnnews.com
Did You Suffer Losses in Exelixis, Inc. (EXEL)? Contact Levi & Korsinsky About Securities Fraud Claims - ACCESS Newswire
Exelixis Q2 net product revs down 2% at $531.3mln, below consensus. - AInvest
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc.EXEL - MarketScreener
Momentum Screeners Rank Exelixis Inc. in Top 5 TodayQuarterly Market Review & Scalable Portfolio Growth Ideas - newsimpact.co.kr
Will Exelixis Inc. continue its uptrendJuly 2025 Action & Expert Curated Trade Setups - Newser
Is it too late to sell Exelixis Inc.Quarterly Growth Report & AI Forecast for Swing Trade Picks - Newser
EXEL Investor Notice: Levi & Korsinsky Investigates Exelixis, Inc. for Securities Law Violations - ACCESS Newswire
Pan-Tumor Rollover Study: Bristol-Myers Squibb, Exelixis, and Novartis Collaborate on Long-Term Cancer Treatment - AInvest
Investigation Underway: Exelixis, Inc. (EXEL)Contact Levi & Korsinsky Over Securities Law Violations - ACCESS Newswire
Exelixis Q2 2025 presentation slides: Cabozantinib franchise grows 19% YoY By Investing.com - Investing.com Canada
Statistical indicators supporting Exelixis Inc.’s strengthJuly 2025 Retail & Fast Entry High Yield Tips - Newser
Exelixis Inc. Builds Base for Possible ReboundJuly 2025 Highlights & Safe Capital Growth Plans - sundaytimes.kr
Exelixis, Inc. (EXEL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Investors in Exelixis, Inc. (EXEL) Warned of Potential Securities FraudContact Levi & Korsinsky Today - ACCESS Newswire
Ongoing Securities Investigation into Exelixis, Inc. (EXEL)Contact Levi & Korsinsky - ACCESS Newswire
Exelixis Gains 15.6% YTD: How Should You Play the Stock? - The Globe and Mail
Exelixis Inc. Rebounds From Oversold Zone — Now What2025 Stock Rankings & AI Forecast for Swing Trade Picks - mustnews.co.kr
Lost Money on Exelixis, Inc. (EXEL)? Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire
Will Zanzalintinib Ease Out EXEL's Reliance on Cabometyx for Growth? - Yahoo Finance
PNC Financial Services Group Inc. Acquires 1,029 Shares of Exelixis, Inc. (NASDAQ:EXEL) - Defense World
Exelixis (EXEL) Price Target Lowered by HC Wainwright, Analysts Maintain Overall Positive Outlook - AInvest
Exelixis, Inc. (EXEL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
What Fibonacci levels say about Exelixis Inc. reboundWeekly Stock Movement Prediction Watchlist - Newser
Exelixis stock price target lowered to $46 at H.C. Wainwright on SCCHN trial halt - Investing.com Nigeria
Exelixis Inc Stock (EXEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Exelixis Inc Stock (EXEL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| WYSZOMIERSKI JACK L | Director |
Jun 03 '25 |
Sale |
43.09 |
7,535 |
324,683 |
358,882 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):